MaxCyte, Inc. Consolidation of Trading Lines (2025C)
February 21 2022 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 2025C
MaxCyte, Inc.
21 February 2022
MaxCyte, Inc.
("MaxCyte" or the "Company")
Consolidation of Trading Lines
Total voting rights
Gaithersburg, Maryland - 21 February 2022: MaxCyte, Inc.
(Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling
platform technologies for ex-vivo cell engineering, announces the
consolidation of the two lines of common stock into a single
unrestricted line of common stock (MXCT). This will be affected by
the transfer of all stock comprising the Regulation S restricted
trading line (MXCN) to the unrestricted common stock (MXCT) trading
line.
This consolidation of trading lines follows the expiration of
the distribution compliance period in relation to the subscription
of new shares of common stock announced by the Company on 3
February 2021. The consolidation is intended to help both trading
liquidity and transparency for shareholders and will result in the
cancellation of trading of the Regulation S restricted trading line
MXCN (ISIN Number USU575801258).
Currently MaxCyte common stock of $0.01 par each ("Common
Stock") are held as:
(i) unrestricted Common Stock trading under the symbol MXCT
(ISIN number US57777K1060)
(ii) restricted Common Stock trading under the symbol MXCN (ISIN
number USU575801258 )
Following a recent exercise of options and issue of new Common
Stock, the number of unrestricted shares of Common Stock currently
trading under the symbol MXCT is 100,956,992 and the number of
restricted shares of Common Stock currently trading under the
symbol MXCN is 330,000.
The Consolidation will be effective from 25 February 2022,
following which 101,286,992 MaxCyte Common Stock will be held as
unrestricted shares in MXCT. Shareholders in the Company may use
this figure as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the stock capital of the
Company.
Further details regarding the restricted shares
On the 3 February 2021 the Company announced details of
distribution restrictions in respect of certain shares of new
common stock subscribed for at that time. The Company intends to
transfer the restricted shares held by non-affiliates (as defined
under the US Securities Act of 1933, as amended (the "Securities
Act")) of the Company (including those holders who are affiliates
only by virtue of their position as an officer or director of the
Company) to the unrestricted line of Common Stock. As this includes
all of the restricted shares the Company will also be cancelling
the restricted trading line.
While the restricted shares are identical in all respects to the
Company's Common Stock, free from all liens, charges and
encumbrances of any kind, during the "distribution compliance
period", (as set out under Regulation S under the Securities Act)
they are subject to the conditions listed under section 903(b)(3),
or Category 3, of Regulation S.
The distribution compliance period has now ended and accordingly
the restrictions will be lifted shortly and the trading line with
the symbol MXCN.L and ISIN USU575801258 will cease trading at
4:30pm on 24 February 2022. All shareholders on the MXCN.L share
register at 6:00pm on 24 February 2022 (Record Date) will have
their shareholding in Common Stock transferred to the
non-restricted share register. From 25 February 2022 all MaxCyte
Common Stock will trade under the symbol MXCT.L, ISIN number
US57777K1060.
For further information, please contact:
MaxCyte Contacts:
US IR Adviser +1 415-937-5400
Gilmartin Group ir@maxcyte.com
David Deuchler, CFA
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. Over the past 20
years, we have developed and commercialized our proprietary Flow
Electroporation(R) platform, which facilitates complex engineering
of a wide variety of cells. Our ExPERT(TM) platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM)
GTx(TM)and VLx(TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSELFESEESESE
(END) Dow Jones Newswires
February 21, 2022 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024